North Star Asset Management Inc. Lowers Stock Holdings in Eli Lilly and Company $LLY

North Star Asset Management Inc. cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 13.4% during the third quarter, HoldingsChannel.com reports. The fund owned 13,508 shares of the company’s stock after selling 2,098 shares during the quarter. North Star Asset Management Inc.’s holdings in Eli Lilly and Company were worth $10,307,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Waddell & Associates LLC grew its position in shares of Eli Lilly and Company by 5.8% during the 3rd quarter. Waddell & Associates LLC now owns 5,880 shares of the company’s stock worth $4,486,000 after buying an additional 322 shares in the last quarter. Zhang Financial LLC lifted its stake in Eli Lilly and Company by 1.0% in the third quarter. Zhang Financial LLC now owns 2,607 shares of the company’s stock worth $1,989,000 after acquiring an additional 27 shares during the period. Prestige Wealth Management Group LLC grew its holdings in Eli Lilly and Company by 1.2% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 2,068 shares of the company’s stock worth $1,578,000 after acquiring an additional 25 shares in the last quarter. Tableaux LLC purchased a new position in Eli Lilly and Company during the 3rd quarter valued at about $697,000. Finally, Cozad Asset Management Inc. raised its holdings in shares of Eli Lilly and Company by 3.5% in the 3rd quarter. Cozad Asset Management Inc. now owns 22,457 shares of the company’s stock valued at $17,135,000 after purchasing an additional 762 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on LLY shares. Cantor Fitzgerald increased their price objective on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. National Bank Financial set a $1,286.00 target price on Eli Lilly and Company in a research report on Monday, December 1st. TD Cowen boosted their price target on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Argus upped their price objective on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, Leerink Partners lifted their target price on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,229.33.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,042.68 on Wednesday. The company has a 50 day moving average price of $1,054.49 and a 200 day moving average price of $923.72. The firm has a market capitalization of $983.62 billion, a P/E ratio of 45.43, a PEG ratio of 1.23 and a beta of 0.39. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm’s revenue was up 42.6% on a year-over-year basis. During the same quarter last year, the business earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is 30.15%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial news showing Novo’s next‑gen obesity candidate underperformed Lilly’s tirzepatide has strengthened expectations that Lilly will retain market share in the high-growth weight‑loss category; that data triggered earlier upside in LLY. Trial Readout Lifts Lilly
• Positive Sentiment: Lilly launched an FDA‑cleared multi‑dose KwikPen for Zepbound (tirzepatide), giving patients a more convenient monthly device at the same self‑pay price — a commercial move intended to improve adherence and retention. Zepbound KwikPen Launch
• Positive Sentiment: Wall Street remains constructive on LLY’s longer‑term outlook (Goldman and other analysts keep Buy/Outperform calls and elevated price targets), supporting the stock’s valuation against the sector noise. Analyst Support
• Neutral Sentiment: Early clinical work showing benefit of combining Zepbound with other therapies (e.g., Taltz) and investor commentary on retention strategies (multi‑dose pen) add incremental optionality but are not immediate revenue drivers. Pipeline/Combo Data
• Negative Sentiment: Nuevo pricing shock — Novo Nordisk announced U.S. list price cuts of up to ~50% for Ozempic/Wegovy (to ~$675/month starting 2027). That move has rattled the sector, and LLY shares have slipped as investors reassess pricing dynamics and potential margin/market‑share impacts across GLP‑1s. Novo Price Cut Hits Stocks
• Negative Sentiment: Broader competition and pricing pressure could compress realized prices or accelerate payer negotiations over time, a structural risk to growth if competitors follow price cuts or insurers demand steeper discounts. Price Competition Risk

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.